Merck Targets Sandoz, Intas Over Generic Emend Plans

Law360, New York (June 05, 2012, 9:34 PM ET) -- Merck Sharp & Dohme Corp. is suing Novartis AG unit Sandoz Inc. and India-based Intas Pharmaceuticals Ltd., claiming their plans to make a generic version of Merck's anti-nausea drug Emend would infringe two patents.

In two complaints filed May 31 and June 1 in the District of New Jersey, Merck said the abbreviated new drug applications filed by Sandoz and Intas' American unit Accord Healthcare Inc. infringe U.S. Patent Numbers 5,691,336 and 5,716,942, held by Merck.

Merck is asking for an injunction preventing Sandoz and Accord...
To view the full article, register now.